MedPath

Use of Export in Primary Percutaneous Coronary Intervention

Not Applicable
Recruiting
Conditions
Total Occlusion of Coronary Artery
Primary Percutaneous Coronary Intervention
ST-segment Elevation Myocardial Infarction (STEMI)
Interventions
Device: Balloon catheter
Device: Export Catheter
Registration Number
NCT05510661
Lead Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Brief Summary

Aim of this single center randomized open label trial with blinded in-hospital outcomes assessment is designed with aim to compare manual thrombus aspiration followed by percutaneous coronary intervention (PCI) strategy with PCI alone.

Detailed Description

Clinical benefit of manual aspiration has been a contentious point of debate and it is Class III indication in current clinical practice guidelines, however, recent observational data by Kumar D et al. showed benefits of usage of export in terms of favorable in-hospital outcomes and lesser complication rate in patients with total occlusion, furthermore, benefits of usage of export was observed to be directly associated with duration of chest pain at the time of thrombus aspiration. However, these observations are limited to immediate and in-hospital outcomes and data regarding efficacy of manual thrombus aspiration are not available.

Hence this single center randomized open label trial is designed with specific aim to test the following hypothesis for STEMI patients with total occlusion undergoing primary PCI;

* Whether use of export catheter reduces in-hospital and short term adverse events

* Whether use of export reduces slow flow or no reflow

* Whether use of export reduces the use of intracoronary drugs

* Whether use of export within 6 hours of symptom onset significantly reduces in-hospital and short term adverse events

Consecutively recruited patients will be randomized to either primary PCI with export or primary PCI alone group in 2:1 ratio. Post aspiration immediate TIMI flow will be observed and all the patients will be observed for adverse outcomes (MACE) and complications including slow flow/no-reflow. Follow-up intervals will be at the end of one month of randomization and end of 6 month of randomization.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patients presenting with:-Symptoms of myocardial ischemia lasting for ≥30 minutes
  • Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads
  • Chest pain < 12 hours duration
  • Total occlusion (TIMI 0 flow)
  • Patients undergoing primary PCI
  • Informed consent
Exclusion Criteria
  • Patients with prior history of cardiac related surgery or intervention
  • Performance of a rescue PCI after thrombolysis
  • Known existence of a disease resulting in a life expectancy of less than 6 months
  • Killip class III, IV

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupBalloon catheterPredilatation with balloon catheter (≤2.00 mm diameter) followed by primary PCI
Intervention GroupExport CatheterManual thrombus aspiration (use of export catheter) followed by primary PCI
Primary Outcome Measures
NameTimeMethod
Slow/No-reflowImmediately after procedure

TIMI 0-II flow

Post thrombus aspiration TIMI flowImmediately after export/balloon

Immediate TIMI flow after export/balloon

Major adverse cardiac eventsIn-hospital, at 1 month, and at 6 months

It will include All-cause death, Cardiovascular death, Re- infarction, Heart Failure, Cardiogenic shock, Cerebrovascular events, Bleeding events, and Stent thrombosis

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

National Institute of Cardiovascular Diseases

🇵🇰

Karachi, Sindh, Pakistan

© Copyright 2025. All Rights Reserved by MedPath